Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermical (marketed as Dermical Heel Balm) is a topical dermatological product developed and marketed by Austell Pharmaceuticals, a South African pharmaceutical company. The product's primary active ingredient is a high concentration of urea, which functions as a keratolytic agent to soften and remove hyperkeratotic skin. It is specifically indicated for the treatment of dry, cracked heels and the removal of callouses, with clinical data indicating significant efficacy within 14 days of once-daily application. The formulation is designed to be diabetic-friendly, making it suitable for foot care in patients with diabetes who are prone to skin complications such as xerosis and hyperkeratosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermical.